Onxeo Has Applied for Admission to Trading on Nasdaq First North Growth Market Denmark and Delisting from Nasdaq Main Market Copenhagen

Nachrichtenquelle: Business Wire (engl.)
27.11.2020, 18:15  |  148   |   |   

Regulatory News:

Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR), in particular against rare or resistant cancers, has today, applied for the delisting of its securities from Nasdaq Main Market Copenhagen and the admission to trading on Nasdaq First North Growth Market Denmark.

This transfer will occur in connection with the planned transfer of the listing of Onxeo securities from the Euronext Paris regulated market to the Euronext Growth Paris multilateral trading facility in order to align regulatory requirements in both countries and maintain a convenient secondary listing for its Danish shareholders.

Subject to Nasdaq’s approval, the last trading day on Nasdaq Main Market Copenhagen will be 11 December 2020 and the first trading day on Nasdaq First North Growth Market Denmark will be 14 December 2020. The Company will continue to trade under ISIN code FR0010095596 and ticker symbol ONXEO on Nasdaq First North Growth Market.

The Company will no longer be subject to the disclosure requirements in the Capital Markets Act (“Kapitalmarkedsloven”) and shareholders will no longer be required to inform about their shareholdings according to the Capital Markets Act. Instead the Company will be subject to the rules of the Nasdaq First North Growth Market Rulebook that does not have the same company disclosure requirements as the Capital Markets Act and does not require shareholders to report their shareholdings in the Company.

The Company will continue to be subject to the rules and requirements of the Market Abuse Regulation.

Purpose of transfer

The purpose of both transfers is to allow Onxeo to be listed on a market which is more suitable to the Company’s size and its market capitalization. The transfers to Euronext Growth Paris and First North Growth Market Denmark should provide the Company with a regulatory framework that is better suited to a SME and reduce listing-related costs, while still benefiting from access to the financial markets.

Consequences for Onxeo shareholders

Nasdaq Main Market has the legal status of a regulated market, while Nasdaq First North Growth Market is legally considered a SME Growth Market, which is a Multilateral Trading Facility. Upon transfer from the Main Market to First North Growth Market, rules for Danish shareholders are not changed or different as regards taxes and pensions and there is no consequence on the tax treatment of capital gains and losses.

Seite 1 von 3
Onxeo Aktie jetzt über den Testsieger (Finanztest 11/2020) handeln, ab 0 € auf Smartbroker.de



Diesen Artikel teilen

0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

Onxeo Has Applied for Admission to Trading on Nasdaq First North Growth Market Denmark and Delisting from Nasdaq Main Market Copenhagen Regulatory News: Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR), in particular …

Nachrichten des Autors

Titel
Titel
Titel
Titel